Matrix metalloproteinase-3 as a marker of subclinical activity in rheumatoid arthritis patients: Relation to ultrasonographic activity

被引:4
|
作者
Hamdy, Fatma [1 ]
Morad, Nibal [1 ]
Tharwat, Samar [1 ]
Abd El-khalek, Ahmed [2 ]
Mahsoub, Nancy [3 ]
Eltoraby, Ehab [1 ]
Enein, Asmaa [1 ]
机构
[1] Mansoura Univ, Fac Med, Internal Med Dept, Rheumatol & Immunol Unit, Dakahlia, Egypt
[2] Mansoura Univ, Fac Med, Diagnost Radiol Dept, Dakahlia, Egypt
[3] Mansoura Univ, Fac Med, Clin Pathol Dept, Dakahlia, Egypt
来源
EGYPTIAN RHEUMATOLOGIST | 2022年 / 44卷 / 03期
关键词
Rheumatoid arthritis; Remission; Subclinical activity; Matrix metalloproteinase-3; Sonographic activity; DISEASE-ACTIVITY;
D O I
10.1016/j.ejr.2021.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rheumatoid arthritis (RA) isa chronic disease which may result in progressive joint destruc-tion even with clinical remission. Ultrasound (US) can detect subclinical disease activity and matrix met-alloproteinase 3 (MMP-3) has a role in disease activity in RA. Aim of the work: To evaluate the level of MMP-3 in RA patients and its ability to predict sonographic activ-ity in patients with clinical remission or low disease activity (LDA). Patients and methods: This study included 45 RA patients with a disease activity score (DAS28) <3.2 and 45 matched healthy control. US evaluation using modified German US7 score was performed and accord-ingly patients were classified into those with sonographic remission (grey scale 0-1) or activity. MMP-3 level was assessed by enzyme-linked immunosorbent assay. Results. The mean age of the patients was 45 +/- 9.5 years and 86.7% were females. Sonographic remission was achieved in 20 (44.4 %) patients. There was a significant difference in serum MMP-3 between patients and control (17 +/- 4.5 vs 6.3 +/- 2.2 ng/ml; p < 0.0001). There was no difference between patients with clinical remission (n = 37) and those with LDA (n = 8). Serum MMP-3 tended to be higher in patients with sono-graphic activity than in those with sonographic remission (18 +/- 5.3 vs 15.6 +/- 2.8 ng/ml; p = 0.3). Serum MMP-3 significantly correlated with erythrocyte sedimentation rate (p = 0.002) and synovitis score (p = 0.002). Conclusion: Serum MMP-3 was higher in RA patients than in control and was associated with the ultra -sound synovitis score. However, serum MMP-3 was not able to differentiate patients with sonographic remission from those with subclinical activity. (c) 2022 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [1] RELATIONSHIP OF MATRIX METALLOPROTEINASE-3 CONCENTRATION WITH CLINICAL, LABORATORY AND ULTRASONOGRAPHIC MARKERS OF RHEUMATOID ARTHRITIS ACTIVITY
    Flicinski, J.
    Kubis, M.
    Brzezinski, M.
    Kaszuba, M.
    Butkiewicz, F.
    Izbicki, J.
    Lopinski, H.
    Fischer, K.
    Brzosko, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 838 - 839
  • [2] Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis
    Tuncer, Turkan
    Kaya, Arzu
    Gulkesen, Arif
    Kal, Gul Ayden
    Kaman, Dilara
    Akgol, Gurkan
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (05): : 665 - 670
  • [3] Serum matrix metalloproteinase-3 in rheumatoid arthritis patients: Correlation with disease activity and joint destruction
    Fadda, Samia
    Abolkheir, Enas
    Afifi, Rabab
    Gamal, Mohamad
    EGYPTIAN RHEUMATOLOGIST, 2016, 38 (03): : 153 - 159
  • [4] Serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis
    Ates, A
    Türkçapar, N
    Olmez, Ü
    Aydintug, O
    Düzgün, N
    Duman, M
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 400 - 400
  • [5] LIPID PROFILES AND MATRIX METALLOPROTEINASE-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Gerasimova, Elena
    Popkova, Tatiana
    Cherkasova, Maria
    CHEST, 2021, 160 (04) : 258A - 258A
  • [6] Serum and synovial matrix metalloproteinase-3 as markers of disease activity in early rheumatoid arthritis
    Rasha Mohamed Fawzy
    Yasser A. Abdel Hamid
    Mona M. Albehesy
    Rasha F. Aboelmaged
    Egyptian Rheumatology and Rehabilitation, 2016, 43 (4) : 178 - 183
  • [7] Serum Matrix Metalloproteinase-3 in Comparison with Acute Phase Proteins as a Marker of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis
    Ally, Mahmood M. T. M.
    Hodkinson, Bridget
    Meyer, Pieter W. A.
    Musenge, Eustasius
    Tikly, Mohammed
    Anderson, Ronald
    MEDIATORS OF INFLAMMATION, 2013, 2013
  • [8] Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis
    Posthumus, MD
    Limburg, PC
    Westra, J
    Cats, HA
    Stewart, RE
    van Leeuwen, MA
    van Rijswijk, MH
    RHEUMATOLOGY, 1999, 38 (11) : 1081 - 1087
  • [9] Evaluation of matrix metalloproteinase-3 (MMP-3) as a candidate biomarker in assessment of disease activity in Algerian rheumatoid arthritis patients
    Hadjout, T.
    Salah, S.
    Klouche, N.
    Benidir, M.
    Djennane, M.
    Fodil, D.
    Lefkir-Tafiani, S.
    Attal, N.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 947 - 948
  • [10] Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis
    Ribbens, C
    Andre, B
    Jaspar, JM
    Kaye, O
    Kaiser, MJ
    De Groote, D
    Malaise, MG
    JOURNAL OF RHEUMATOLOGY, 2000, 27 (04) : 888 - 893